AIMS: In the context of changes in the last 10 years in treatment strategies for type 1 diabetes we evaluated longitudinal trends in cardiometabolic risk factor profiles in a population from North-West England. METHODS: We retrospectively examined longitudinal case records for the period for 291 adult patients followed up between 2004 and 2009 (age range 16-85). Data search was performed through the EMIS® software provider using data held in primary care. RESULTS: Longitudinal analysis of individually followed patients indicated a mean 0.4% reduction in HbA1c from 8.3% (67 mmol/mol) at baseline (p=0.002). The proportion of patients with an HbA1c ≥10% (86 mmol/mol) at baseline had a significant reduction over time from 14.0% to 9.5% (χ(2)=9.4, p=0.002). BMI remained unchanged (28.3 vs 28.4 kg/m(2)). However total cholesterol fell by 12.5% from 4.8mM to 4.2mM, (p<0.0001) with a corresponding 23% reduction in LDL-cholesterol from 3.0mm to 2.3mM (p<0.0001). There was a significant fall in diastolic BP (78-74 mmHg, p=0.0016). In a mixed longitudinal regression model, HbA1c was associated with LDL-C (β=0.28, p<0.001) and age (β=0.02, p=0.001), independent of BMI, gender and systolic BP. DISCUSSION: In spite of intensive work to improve glycaemic control in type 1 diabetes, mean HbA1c remains above target for many people in our area, highlighting the difficulty of achieving glycaemic targets in type 1 diabetes. The significant reduction in diastolic BP, LDL and total cholesterol may have long-term benefit in cardiovascular event rate reduction.
AIMS: In the context of changes in the last 10 years in treatment strategies for type 1 diabetes we evaluated longitudinal trends in cardiometabolic risk factor profiles in a population from North-West England. METHODS: We retrospectively examined longitudinal case records for the period for 291 adult patients followed up between 2004 and 2009 (age range 16-85). Data search was performed through the EMIS® software provider using data held in primary care. RESULTS: Longitudinal analysis of individually followed patients indicated a mean 0.4% reduction in HbA1c from 8.3% (67 mmol/mol) at baseline (p=0.002). The proportion of patients with an HbA1c ≥10% (86 mmol/mol) at baseline had a significant reduction over time from 14.0% to 9.5% (χ(2)=9.4, p=0.002). BMI remained unchanged (28.3 vs 28.4 kg/m(2)). However total cholesterol fell by 12.5% from 4.8mM to 4.2mM, (p<0.0001) with a corresponding 23% reduction in LDL-cholesterol from 3.0mm to 2.3mM (p<0.0001). There was a significant fall in diastolic BP (78-74 mmHg, p=0.0016). In a mixed longitudinal regression model, HbA1c was associated with LDL-C (β=0.28, p<0.001) and age (β=0.02, p=0.001), independent of BMI, gender and systolic BP. DISCUSSION: In spite of intensive work to improve glycaemic control in type 1 diabetes, mean HbA1c remains above target for many people in our area, highlighting the difficulty of achieving glycaemic targets in type 1 diabetes. The significant reduction in diastolic BP, LDL and total cholesterol may have long-term benefit in cardiovascular event rate reduction.
Authors: Ghasem Yadegarfar; Simon G Anderson; Zohaib Khawaja; Gabriela Cortes; Kathryn Leivesley; Ann Metters; Linda Horne; Tom Steele; Adrian H Heald Journal: Cardiovasc Endocrinol Metab Date: 2020-06-16
Authors: Fernando M A Giuffrida; Alexis D Guedes; Eloa R Rocco; Denise B Mory; Patricia Dualib; Odelisa S Matos; Reine M Chaves-Fonseca; Roberta A Cobas; Carlos Antonio Negrato; Marilia B Gomes; Sergio A Dib Journal: Cardiovasc Diabetol Date: 2012-12-27 Impact factor: 9.951
Authors: Ahmed O Almobarak; Sufian K Noor; Wadie M Elmadhoun; Sarra O Bushara; Reham S Salim; Sittana A Forawi; Heitham Awadalla; Einas S Elwali; Mohamed H Ahmed Journal: J Family Med Prim Care Date: 2017 Apr-Jun
Authors: Ghasem Yadegarfar; Mark Livingston; Gabriela Cortes; Ramadan Alshames; Kate Leivesley; Ann Metters; Linda Horne; Tom Steele; Adrian H Heald Journal: Cardiovasc Endocrinol Metab Date: 2021-03-25